Burotto M - Search Results

1

Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status.

Blagoev KB, Wilkerson J, Burotto M, Kim C, Espinal-Domínguez E, García-Alfonso P, Alimchandani M, Miettinen M, Blanco-Codesido M, Fojo T. Blagoev KB, et al. Among authors: burotto m. PLoS One. 2017 Oct 5;12(10):e0175484. doi: 10.1371/journal.pone.0175484. eCollection 2017. PLoS One. 2017. PMID: 28981524 Free PMC article.

2

Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.

Burotto M, Wilkerson J, Stein W, Motzer R, Bates S, Fojo T. Burotto M, et al. PLoS One. 2014 May 5;9(5):e96316. doi: 10.1371/journal.pone.0096316. eCollection 2014. PLoS One. 2014. PMID: 24796484 Free PMC article. Clinical Trial.

3

Brain metastasis in patients with adrenocortical carcinoma: a clinical series.

Burotto M, Tageja N, Rosenberg A, Mahalingam S, Quezado M, Velarde M, Edgerly M, Fojo T. Burotto M, et al. J Clin Endocrinol Metab. 2015 Feb;100(2):331-6. doi: 10.1210/jc.2014-2650. Epub 2014 Nov 20. J Clin Endocrinol Metab. 2015. PMID: 25412413 Free PMC article.

4

Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

Burotto M, Manasanch EE, Wilkerson J, Fojo T. Burotto M, et al. Oncologist. 2015 Apr;20(4):400-10. doi: 10.1634/theoncologist.2014-0154. Epub 2015 Mar 20. Oncologist. 2015. PMID: 25795635 Free PMC article.

5

Non-inferiority trials: why oncologists must remain wary.

Burotto M, Prasad V, Fojo T. Burotto M, et al. Lancet Oncol. 2015 Apr;16(4):364-6. doi: 10.1016/S1470-2045(15)70129-4. Lancet Oncol. 2015. PMID: 25846084 No abstract available.

6

Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.

Burotto M, Edgerly M, Poruchynsky M, Velarde M, Wilkerson J, Kotz H, Bates S, Balasubramaniam S, Fojo T. Burotto M, et al. Oncologist. 2015 Jul;20(7):725-6. doi: 10.1634/theoncologist.2015-0104. Epub 2015 Jun 3. Oncologist. 2015. PMID: 26040622 Free PMC article. Clinical Trial.

7

The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.

Prasad V, Kim C, Burotto M, Vandross A. Prasad V, et al. Among authors: burotto m. JAMA Intern Med. 2015 Aug;175(8):1389-98. doi: 10.1001/jamainternmed.2015.2829. JAMA Intern Med. 2015. PMID: 26098871 Review.

8

ANG1005 for breast cancer brain metastases: correlation between ¹⁸F-FLT-PET after first cycle and MRI in response assessment.

O'Sullivan CC, Lindenberg M, Bryla C, Patronas N, Peer CJ, Amiri-Kordestani L, Davarpanah N, Gonzalez EM, Burotto M, Choyke P, Steinberg SM, Liewehr DJ, Figg WD, Fojo T, Balasubramaniam S, Bates SE. O'Sullivan CC, et al. Among authors: burotto m. Breast Cancer Res Treat. 2016 Nov;160(1):51-59. doi: 10.1007/s10549-016-3972-z. Epub 2016 Sep 12. Breast Cancer Res Treat. 2016. PMID: 27620882 Free PMC article. Clinical Trial.

9

A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma.

Burotto M, Edgerly M, Velarde M, Balasubramaniam S, Drabkin H, Gormaz JG, O'Sullivan C, Madan R, Fojo T. Burotto M, et al. Oncologist. 2017 Aug;22(8):888-e84. doi: 10.1634/theoncologist.2017-0211. Epub 2017 Jul 5. Oncologist. 2017. PMID: 28679644 Free PMC article. Clinical Trial.

10

Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes.

Burotto M, Wilkerson J, Stein WD, Bates SE, Fojo T. Burotto M, et al. Semin Oncol. 2019 Feb;46(1):83-99. doi: 10.1053/j.seminoncol.2019.01.002. Epub 2019 Jan 26. Semin Oncol. 2019. PMID: 30738604 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

76 results

Search Page